keyword
MENU ▼
Read by QxMD icon Read
search

Latanoprost

keyword
https://www.readbyqxmd.com/read/27913991/24-hour-efficacy-and-ocular-surface-health-with-preservative-free-tafluprost-alone-and-in-conjunction-with-preservative-free-dorzolamide-timolol-fixed-combination-in-open-angle-glaucoma-patients-insufficiently-controlled-with-preserved-latanoprost-monotherapy
#1
Anastasios-Georgios Konstas, Konstadinos G Boboridis, Paraskevas Kapis, Konstantinos Marinopoulos, Irini C Voudouragkaki, Dimitrios Panayiotou, Dimitrios G Mikropoulos, Eirini Pagkalidou, Anna-Bettina Haidich, Andreas Katsanos, Luciano Quaranta
INTRODUCTION: The aim of the present study was to evaluate the 24-h efficacy, tolerability, and ocular surface health with preservative-free (PF) tafluprost and a PF triple drug regimen comprising tafluprost and dorzolamide/timolol fixed combination (DTFC) in open-angle glaucoma patients who were insufficiently controlled with preserved branded or generic latanoprost monotherapy and who exhibited signs or symptoms of ocular surface disease (OSD). METHODS: Prospective, observer-masked, crossover, comparison...
December 2, 2016: Advances in Therapy
https://www.readbyqxmd.com/read/27862086/correlations-of-afap1-gmds-and-ptgfr-gene-polymorphisms-with-intra-ocular-pressure-response-to-latanoprost-in-patients-with-primary-open-angle-glaucoma
#2
X-J Cui, A-G Zhao, X-L Wang
WHAT IS KNOWN AND OBJECTIVE: Genomewide association studies have identified a number of genetic variants that are associated with the development of primary open-angle glaucoma (POAG). This study aimed to explore possible correlations of common single nucleotide polymorphisms (SNPs) in AFAP1, GMDS and PTGFR genes with intra-ocular pressure (IOP) response to latanoprost in POAG patients. METHODS: From January 2012 to December 2014, 135 patients with POAG were enrolled into our study...
November 12, 2016: Journal of Clinical Pharmacy and Therapeutics
https://www.readbyqxmd.com/read/27859240/the-neuroprotective-effect-of-latanoprost-acts-via-klotho-mediated-suppression-of-calpain-activation-after-optic-nerve-transection
#3
Kotaro Yamamoto, Kota Sato, Masayoshi Yukita, Masayuki Yasuda, Kazuko Omodaka, Morin Ryu, Kosuke Fujita, Koji M Nishiguchi, Shigeki Machida, Toru Nakazawa
Latanoprost was first developed for use in glaucoma therapy as an ocular hypotensive agent targeting the prostaglandin F2α (FP) receptor. Subsequently, latanoprost showed a neuroprotective effect, an additional pharmacological action. However, although it is well known that latanoprost exerts an ocular hypotensive effect via the FP receptor, it is not known whether this is also true of its neuroprotective effect. Klotho was firstly identified as the gene linked to the suppression of ageing phenotype: the defect of klotho gene in mice results ageing phenotype such as hypokinesis, arteriosclerosis and short lifespan...
November 15, 2016: Journal of Neurochemistry
https://www.readbyqxmd.com/read/27829990/analysis-of-the-effects-of-preservative-free-tafluprost-on-the-tear-proteome
#4
Sebastian Funke, Sabine Beck, Katrin Lorenz, Marion Kotterer, Dominik Wolters, Natarajan Perumal, Norbert Pfeiffer, Franz H Grus
The purpose of the present study was to assess the ocular surface health status in primary open angle glaucoma (POAG) patients switching from topical application of preserved latanoprost (LT) to preservative-free tafluprost (PFT) by tear proteomic monitoring. Tear fluid of POAG patients showing dry eye symptoms, using LT and switching to PFT as well as tear fluid of healthy controls has been examined. Tear proteome dynamics was monitored over 24 weeks in a first mass spectrometric explorative analysis in a small POAG patient cohort (N = 3)...
2016: American Journal of Translational Research
https://www.readbyqxmd.com/read/27828896/new-classes-of-glaucoma-medications
#5
Emily M Schehlein, Gary D Novack, Alan L Robin
PURPOSE OF REVIEW: To discuss recent advances in the medical management of glaucoma and to highlight future medical therapies currently in development. RECENT FINDINGS: In 1996, latanoprost (Xalatan) was approved in the United States as a new chemical entity and new class (prostaglandin analogs) for the topical treatment of ocular hypertension and glaucoma. In the period from the late 1990s-2010s, while there were additional new chemical entities, fixed dose combinations, and formulation improvements, there were no new classes of ocular hypotensive medications approved worldwide...
November 8, 2016: Current Opinion in Ophthalmology
https://www.readbyqxmd.com/read/27828721/change-in-central-corneal-thickness-after-the-discontinuation-of-latanoprost-in-normal-tension-glaucoma-change-in-central-corneal-thickness-after-stop-of-latanoprost
#6
Romi Yoo, Youn A Choi, Byung Joo Cho
PURPOSE: To assess the impact of latanoprost on central corneal thickness (CCT) after ceasing medication in patients with normal tension glaucoma (NTG). METHODS: A total of 46 eyes from 46 NTG patients, and 44 eyes from 44 individuals with glaucoma suspect (controls), were included in this retrospective study. Newly diagnosed early NTG patients (visual field mean deviation >-6.00) were administered latanoprost 0.005% monotherapy once a day. CCTs were measured by ultrasound pachymetry before treatment, for 5 years during treatment, and for 2 years after ceasing treatment...
November 9, 2016: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/27800256/transpupillary-argon-laser-cyclophotocoagulation-in-a-refractory-traumatic-glaucoma-patient-with-aphakia-and-aniridia
#7
Umut Duygu Uzunel, Berna Yüce, Tuncay Küsbeci, Halil Ateş
We present a case of transpupillary argon laser cyclophotocoagulation (TALC) in a patient with traumatic aniridia and aphakia secondary to blunt trauma who had previous bilateral trabeculectomy. Four months after the trauma the patient's intraocular pressure (IOP) rose to 35 mmHg despite topical antiglaucomatous medication. Inferior 180 degrees cyclophotocoagulation was performed with transpupillary argon laser in the first session and his IOP fell to values of 12-17 mmHg. Twelve weeks after TALC, his IOP rose to 22 mmHg and we had to apply TALC to the residual ciliary processes...
January 2016: Turkish Journal of Ophthalmology
https://www.readbyqxmd.com/read/27799736/efficacy-and-tolerability-of-benzalkonium-chloride-free-travoprost-in-glaucoma-patients-switched-from-benzalkonium-chloride-preserved-latanoprost-or-bimatoprost
#8
Julian García-Feijoo, Francisco J Muñoz-Negrete, Douglas A Hubatsch, Gemma C Rossi
INTRODUCTION: The preservative benzalkonium chloride (BAK) is used to preserve several topical, intraocular pressure (IOP)-lowering glaucoma medications but can cause tolerability concerns that may lead to decreased adherence to treatment and ultimately diminish the effectiveness of IOP control. The study aimed to determine the efficacy and tolerability of BAK-free travoprost preserved with polyquaternium-1 in glaucoma patients switched from BAK-preserved latanoprost or bimatoprost. METHODS: This 12-week, open-label study was conducted in Europe between December 2011 and February 2013...
2016: Clinical Ophthalmology
https://www.readbyqxmd.com/read/27791324/effect-of-topical-ophthalmic-latanoprost-0-005-solution-alone-and-in-combination-with-diclofenac-0-1-solution-in-healthy-horses-a-pilot-study
#9
Kyle Tofflemire, Elizabeth M Whitley, Rachel Allbaugh, Gil Ben-Shlomo, Angela Griggs, Travis Strong, R David Whitley
OBJECTIVE: To evaluate the effect of topical ophthalmic 0.005% latanoprost alone and in combination with 0.1% diclofenac on healthy horses. ANIMALS STUDIED: Twelve healthy adult horses. PROCEDURES: A randomized, masked crossover design was used with horses divided into three groups for once daily treatment in one randomly selected eye. For arm 1 of the study, Group D (n = 3) received 0.1% diclofenac, Group L (n = 3) received 0.005% latanoprost, and Group DL (n = 6) received 0...
October 28, 2016: Veterinary Ophthalmology
https://www.readbyqxmd.com/read/27767427/effects-of-perioperative-topical-dorzolamide-hydrochloride-timolol-maleate-administration-on-incidence-and-severity-of-postoperative-ocular-hypertension-in-dogs-undergoing-cataract-extraction-by-phacoemulsification
#10
Rachel B Matusow, Ian P Herring, J Phillip Pickett, Natalia Henao-Guerrero, Stephen R Werre
OBJECTIVE To assess the effects of topically applied 2% dorzolamide hydrochloride-0.5% timolol maleate ophthalmic solution (DHTM) on incidence and severity of postoperative ocular hypertension (POH; ie, intraocular pressure [IOP] > 25 mm Hg) in dogs undergoing cataract extraction by phacoemulsification. DESIGN Randomized, masked, controlled study. ANIMALS 103 dogs (180 eyes). PROCEDURES Pertinent history, signalment, and ophthalmic examination findings were recorded. Dogs received 1 drop of DHTM or sham treatment solution (sterile, buffered, isotonic eye drops) in both eyes 14 hours and 2 hours before anesthetic induction and at the time of corneal incision closure (ie, end of surgery); IOPs were assessed by rebound tonometry 2, 4, 6, and 8 hours after surgery and between 7:30 and 8:00 am on the following day...
November 1, 2016: Journal of the American Veterinary Medical Association
https://www.readbyqxmd.com/read/27764023/sustained-drug-delivery-for-glaucoma-current-data-and-future-trends
#11
Ahmad A Aref
PURPOSE OF REVIEW: Sustained drug delivery has been recognized as a need for patients with ocular hypertension or glaucomatous optic neuropathy. Several sustained drug delivery systems and devices are currently on the horizon. This review aims to summarize initial results with these platforms, as reported in the literature, and also provide insight into their possible role in the glaucoma treatment paradigm. RECENT FINDINGS: Sustained drug delivery systems currently on the horizon include the topical bimatoprost ocular insert, travoprost and latanoprost punctal plugs, latanoprost-eluting contact lenses, bimatoprost and travoprost intraocular implants, as well as several other therapies in earlier stages of development...
October 19, 2016: Current Opinion in Ophthalmology
https://www.readbyqxmd.com/read/27749098/cytotoxic-effect-of-latanoprost-on-human-corneal-stromal-cells-in-vitro-and-its-possible-mechanisms
#12
Jun-Wei Shen, Ming Shan, Yuan-Yuan Peng, Ting-Jun Fan
PURPOSE: To investigate the cytotoxic effect of latanoprost on corneal stroma and its underlying cellular and molecular mechanisms using non-transfected human corneal stromal (HCS) cells as an in vitro model. METHODS: After HCS cells were treated with latanoprost at concentrations varying from 50 mg/l (clinical therapeutic dosage) to 0.78125 mg/l, and cell morphology, cell viability, and cell cycle were detected by light microscopy, methyl thiazolyl tetrazolium assay, and flow cytometry (FCM) with propidium iodide (PI) staining, respectively...
October 17, 2016: Current Eye Research
https://www.readbyqxmd.com/read/27601879/comparison-study-of-intraocular-pressure-reduction-efficacy-and-safety-between-latanoprost-and-tafluprost-in-japanese-with-normal-tension-glaucoma
#13
Yoko Ikeda, Kazuhiko Mori, Kaori Tada, Morio Ueno, Shigeru Kinoshita, Chie Sotozono
PURPOSE: To evaluate and compare the intraocular pressure (IOP) reduction efficacy and safety between the ophthalmic solutions 0.005% latanoprost (Lat) and 0.0015% tafluprost (Taf) in Japanese patients with normal-tension glaucoma (NTG). METHODS: In this randomized nonmasked study, we prospectively enrolled 30 Japanese NTG patients who had used Lat monotherapy for more than 4 weeks, and randomly divided them into the following two groups: 1) Lat-to-Taf group (LT group) and 2) Taf-to-Lat group (TL group)...
2016: Clinical Ophthalmology
https://www.readbyqxmd.com/read/27600897/-prostaglandin-analogues-in-glaucoma-treatment
#14
Z A Dzhumataeva
AIM: to evaluate the effectiveness of prolatan (latanoprost 0.005%) in the treatment of primary open-angle glaucoma (POAG). MATERIAL AND METHODS: The study included 35 POAG patients (41 eyes) aged 55-72 years, of them 20 men and 15 women. The patients were randomized into two groups followed up for 3 months. Group 1 consisted of 17 patients (19 eyes) who received prolatan once daily in the evening. Group 2 consisted of 18 patients (22 eyes) under Xalatan 0.005% once daily in the evening...
July 2016: Vestnik Oftalmologii
https://www.readbyqxmd.com/read/27586444/latanoprost-eluting-contact-lenses-in-glaucomatous-monkeys
#15
Joseph B Ciolino, Amy E Ross, Rehka Tulsan, Amy C Watts, Rong-Fang Wang, David Zurakowski, Janet B Serle, Daniel S Kohane
PURPOSE: To assess the ability of latanoprost-eluting contact lenses to lower the intraocular pressure (IOP) of glaucomatous eyes of cynomolgus monkeys. DESIGN: Preclinical efficacy study of 3 treatment arms in a crossover design. PARTICIPANTS: Female cynomolgus monkeys with glaucoma induced in 1 eye by repeated argon laser trabeculoplasty. METHODS: Latanoprost-eluting low-dose contact lenses (CLLO) and high-dose contact lenses (CLHI) were produced by encapsulating a thin latanoprost-polymer film within the periphery of a methafilcon hydrogel, which was lathed into a contact lens...
October 2016: Ophthalmology
https://www.readbyqxmd.com/read/27567675/-unpreserved-latanoprost-in-the-treatment-of-open-angle-glaucoma-and-ocular-hypertension-a-multicenter-randomized-controlled-study
#16
P Denis
OBJECTIVES: To evaluate the safety and efficacy of unpreserved latanoprost eye drops (UNL) in comparison with preserved latanoprost eye drops (LBAK) in patients with glaucoma or ocular hypertension stabilized with preserved latanoprost eye drops as monotherapy. METHODS: Multicenter, randomized, open, two-parallel group study. The intraocular pressure (IOP), ocular signs and symptoms, adverse events and a quality of life questionnaire were evaluated at inclusion (D0) and after 3 months of treatment (D84)...
September 2016: Journal Français D'ophtalmologie
https://www.readbyqxmd.com/read/27565224/randomized-controlled-phase-3-trials-of-carteolol-latanoprost-fixed-combination-in-primary-open-angle-glaucoma-or-ocular-hypertension
#17
Tetsuya Yamamoto, Toru Ikegami, Yuji Ishikawa, Satoru Kikuchi
PURPOSE: To assess the intraocular pressure (IOP)-lowering effects and safety of a carteolol/latanoprost fixed combination drug (OPC-1085EL) versus latanoprost (Study 1) and carteolol (Study 2) in patients with primary open angle glaucoma (POAG) or ocular hypertension (OH). DESIGN: Multicenter, randomized, evaluator-masked (Study 1)/double-masked (Study 2), parallel-group studies. METHODS: Setting: Twenty-eight clinical sites (Study 1) and 19 clinical sites (Study 2) in Japan...
August 23, 2016: American Journal of Ophthalmology
https://www.readbyqxmd.com/read/27556218/the-combination-of-plgf-inhibition-and-mmc-as-a-novel-anti-scarring-strategy-for-glaucoma-filtration-surgery
#18
Tine Van Bergen, Bart Jonckx, Lieve Moons, Jean H M Feyen, Ingeborg Stalmans
PURPOSE: The complementary effects of mitomycin-C (MMC) and anti-placental growth factor (PlGF) therapy were explored and compared to the combined administration of MMC and aflibercept. Additionally, the effect of PlGF (inhibition) on IOP was investigated, since aqueous PlGF is known to be upregulated in glaucoma patients. METHODS: In the trabeculectomy mouse model, intracameral injection(s) of the PlGF inhibitor (5D11D4) were compared to MMC or aflibercept and to the combination of both compounds...
August 1, 2016: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/27506567/does-the-intraocular-pressure-lowering-effect-of-prostaglandin-analogues-continue-over-the-long-term
#19
Caner Kara, Emine Malkoç Şen, Kadriye Ufuk Elgin, Kurtuluş Serdar, Pelin Yilmazbaş
The purpose of the study is to assess the changes in the long-term effects of prostaglandin analogues (PGAs) on intraocular pressure (IOP) reduction in patients with primary open-angle glaucoma (POAG). Data of POAG patients treated with latanoprost (0.005 %), travoprost (0.004 %), or bimatoprost (0.03 %) as the first line treatment for 5 years or more were retrospectively evaluated. Baseline ophthalmic assessment values were recorded together with the IOP at the 6th month, 1st year, and then annually. The 79 patients included 33 (41...
August 9, 2016: International Ophthalmology
https://www.readbyqxmd.com/read/27463221/ocular-penetration-and-pharmacokinetics-of-ripasudil-following-topical-administration-to-rabbits
#20
Tomoyuki Isobe, Taku Kasai, Hiroyuki Kawai
PURPOSE: We evaluated the ocular pharmacokinetics of ripasudil (K-115), a selective Rho-associated coiled-coil containing protein kinase (ROCK) inhibitor, following topical administration to rabbits. METHODS: We determined the ocular distribution of [(14)C]ripasudil by whole-head autoradiography and the radioactivity of each ocular tissue after single and multiple instillation of [(14)C]ripasudil to pigmented rabbits. We also measured the aqueous humor concentrations after concomitant instillation of ripasudil and a combination agent (0...
September 2016: Journal of Ocular Pharmacology and Therapeutics
keyword
keyword
121100
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"